IP Library Granted Patent US 10,738,309
Granted Patent B2
US 10,738,309 · App. 15/928,494 · Granted Aug 11, 2020

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

Inventor: Giovanni Monteleone (Grottaferrata, IT)
Assignee: Nogra Pharma Limited
C12N15/1136C12N15/113A61K38/00A61K48/00C12N2310/11C12N2310/314C12N2310/315C12N2310/3125C12N2310/321C12N2310/334C12N2310/3341C12N2310/344C12N2310/3521C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,309
App. No.
15/928,494
Granted
Aug 11, 2020
Kind
B2
Abstract

The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Claims (3)

1. An antisense oligonucleotide against Smad7 consisting of SEQ ID NO: 11 (5′-XGAACATGACCTCXGCAC-3′), wherein X is 5-methyl-2′-deoxycytidine 5′-monophosphate.

2. A method of treating ulcerative colitis, the method comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .

3. A method of treating inflammatory bowel disease, the method comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: MONTELEONE, GIOVANNI
To: GIULIANI INTERNATIONAL, LTD.
Reel/Frame 052070/0031 →
CHANGE OF NAME Recorded Mar 10, 2020
From: GIULIANI INTERNATIONAL LIMITED
To: NOGRA PHARMA LIMITED
Reel/Frame 052135/0832 →